Rosuvastatin uses and dose and total duration of treatment
Reading File
Finding Sources
Searching the Web
rosuvastatin uses doses duration of treatment guidelines 2024
Finding Sources
Finding Sources
Finding Sources
Reading Web Page
https://www.statpearls.com/point-of-care/31521
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information. Let me compile the full answer.
Rosuvastatin - Uses, Dose, and Duration of Treatment
Drug Class and Mechanism
Rosuvastatin is an HMG-CoA reductase inhibitor (statin). It inhibits HMG-CoA reductase, the key enzyme in hepatic cholesterol biosynthesis. This leads to increased LDL receptor expression in the liver, accelerated clearance of circulating LDL, and a dose-dependent reduction in plasma LDL-C. - Harrison's Principles of Internal Medicine 22E (2025)
Indications (Uses)
FDA-Approved Uses
| Indication | Notes |
|---|---|
| Primary hyperlipidemia / mixed dyslipidemia | Reduces LDL-C, total cholesterol, TGs; raises HDL-C |
| Hypertriglyceridemia | Significant TG reduction at higher doses |
| Primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) | |
| Homozygous familial hypercholesterolemia (HoFH) | Adults and children ≥7 years |
| Heterozygous familial hypercholesterolemia (HeFH) | Adults and children ≥8 years |
| Primary prevention of ASCVD events | Reduces risk of nonfatal MI, nonfatal stroke, CV death, arterial revascularization in adults without established CHD who have: age-related risk + hs-CRP ≥2 mg/L + ≥1 additional CV risk factor (based on the JUPITER trial) |
Off-Label Uses
- Secondary prevention of transient ischemic attack (TIA) and noncardioembolic stroke
- Perioperative cardiac risk reduction in noncardiac surgery
- Acute ischemic stroke
- Reducing mortality/rejection in heart transplant recipients
Dosing
Rosuvastatin is taken orally, once daily, at any time of day, with or without food. Dose adjustments occur at intervals of at least 4 weeks.
Adults - By Intensity (AHA/ACC Classification)
| Intensity | Dose | Expected LDL-C Reduction |
|---|---|---|
| Low-intensity | 5 mg once daily | ~30% |
| Moderate-intensity | 5-10 mg once daily | 30-49% |
| High-intensity | 20-40 mg once daily | ≥50% |
| Maximum dose | 40 mg/day | - |
- Usual starting dose: 10-20 mg/day
- High-intensity therapy (20-40 mg) is recommended for patients with established ASCVD or very high cardiovascular risk
- For primary prevention, moderate-intensity (5-10 mg) is often appropriate
Special Populations
| Population | Dosing Guidance |
|---|---|
| Asian patients | Start at 5 mg once daily (plasma levels ~2-fold higher than in White patients) |
| Severe renal impairment (CrCl <30 mL/min) | Start at 5 mg once daily; do not exceed 10 mg/day |
| Children with HeFH (ages 8-10) | 5-10 mg once daily |
| Children with HeFH (ages >10) | 5-20 mg once daily |
| Children with HoFH (ages ≥7) | 20 mg once daily |
| Drug interaction: cyclosporine | Maximum 5 mg/day |
| Drug interaction: certain antiretrovirals | Dose reduction required; some combinations contraindicated |
| Pregnancy / breastfeeding | Contraindicated |
Note: Rosuvastatin and pravastatin are generally better tolerated than other statins in patients with a history of myalgias. - Goodman & Gilman's Pharmacological Basis of Therapeutics
Duration of Treatment
Statins are generally considered lifelong therapy when prescribed for:
- Established ASCVD (secondary prevention)
- Familial hypercholesterolemia (HoFH or HeFH)
- High 10-year ASCVD risk (≥7.5%)
The key principle from current guidelines (Harrison's 2025, 2018 AHA/ACC Cholesterol Guideline) is that statin therapy continues as long as LDL-C remains above goal (typically >70 mg/dL in high-risk and >55 mg/dL in very high-risk patients) and the patient tolerates it. Discontinuing statin therapy in secondary prevention is associated with increased MACE risk.
- In primary prevention at borderline risk, the decision to continue is reassessed based on shared decision-making, risk-benefit balance, and patient preference.
- There is no fixed maximum duration - monitoring typically involves lipid panels at 4-12 weeks after initiation or dose change, then annually once stable.
- Elderly patients already tolerating high-dose statins should generally continue; guidelines do not recommend dose reduction solely based on age. - Braunwald's Heart Disease
Key Safety Monitoring
- Muscle symptoms: Myalgia in 3-5% of patients; measure CK if symptomatic; rare risk of rhabdomyolysis
- Liver transaminases: Usually mild and transient elevation; no routine monitoring required unless symptomatic
- Blood glucose/HbA1c: Small increased risk of new-onset type 2 diabetes; cardiovascular benefits outweigh this risk
- Proteinuria/hematuria: Monitor urine protein if dose exceeds 40 mg
Sources: Harrison's Principles of Internal Medicine 22E (2025); Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung's Basic and Clinical Pharmacology 16th Edition; FDA CRESTOR Prescribing Information (July 2024); StatPearls (2025)
This is a shared conversation. Sign in to Orris to start your own chat.